According to GlaxoSmithKline Plc. and XenoPort Inc. migraine experimental drug GSK 1838262 (also known as XP 13512) did not achieve clinical objectives compared to placebo in adult patients.

Novo Nordisk A/S presented at the American Diabetes Association Congress, data of Phase II clinical trial, that showed injectable insulin drug, Degludec, to be effective once-daily and three-times-weekly in diabetes patients.

According to a Phase III study results, presented by Bristol-Myers Squibb Co. and AstraZeneca Plc. experimental diabetes Type 2 drug, Dapagliflozin, showed to be more effective than placebo. The study enrolled 800 patients.

At the request of the Food and Drug Administration, Pfizer Inc. stopped clinical trials of osteoarthritis experimental drug, Tanezumab. According to reports, patients conditions worsened and led to joint replacements.

Novo Nordisk A/S announced Phase III trials re-initiation of GLP1 drug, Victoza (Liraglutide) indicated to treat obesity.

Amylin Pharmaceuticals Inc. and Eli Lilly & Co. presented mixed Phase III results for weekly experimental diabetes type 2 drug, Bydureon (Exenatide for Extended-Release Injectable Suspension). The drug belongs to the GLP1 family.

Pfizer announced development discontinuation of Trubion Pharmaceuticals Inc. experimental drug TRU 015, currently in Phase II, after failing to comply with primary clinical objectives combined with methotrexate.

Bayer AG y Onyx Pharmaceuticals Inc., drug Nexavar (Sorafenib), did not meet late stage objectives as first line treatment for non squamous cell advanced non-small cell lung cancer. The drug was tested versus placebo in combination with two chemotherapeutic agents.

Merck & Co. insomnia experimental drug, MK 4305, showed positive results on Phase IIb trial that enrolled more than 500 patients. The drug is on going to late stages of development, and could be submitted for approval by 2012.

Vivus Inc. announced results of their second Phase III trial for experimental drug, Avanafil, indicated to treat erectile dysfunction. The drug met clinical objectives in the two doses tested.

Bristol-Myers Squibb Co. Announced positive results for Phase III experimental skin cancer drug Ipilimumab. The drug is a result of 2009 Medarex Inc. acquisition. The drug increased 67 percent survival or almost four months.

Novartis AG said that their cancer drug Afinitor (Everolimus) met late stage clinical objectives on patients with advanced pancreatic cancer, the drug extended progression-free survival, or time without tumor growth. EMEA and FDA documentation will be submitted during this year.

Japanese Shionogi & Co. Presented results of two late stage clinical trials, at the Annual meeting of the American Urological Association, for a topical metered dose spray, indicated to treat primary premature ejaculation, known as PSD 506 (Lidocaine + Prilocaine).

Pfizer Inc. announced that they have stopped recruitment of patients for Phase IIIb clinical trial for experimental heart drug, Inspra (Eplerenone) indicated to reduce risk of heart attack or heart failure.

Sanofi-Aventis SA announced that experimental prostate cancer drug, Cabazitaxel combined with Prednisone/Prednisolone, reduced risk of death by 28 percent compared to a controlled group of patients administered with chemotherapy combined with Mitoxantrone+ Prednisone/Prednisolone.

Novartis AG announced that ovarian cancer drug, Patupilone (EPO 906) did not meet global study late stage clinical objectives.

Vertex Pharmaceuticals Inc. announced Phase III results for Hepatitis C experimental drug, Telaprevir. It showed that the drug is faster and more effective compared to standard treatment. The viral drug in jointly developed with Johnson & Johnson Inc.

Abbott Laboratories Inc. and Biogen Idec Inc. started phase III for biological experimental drug Daclizumab, indicated to treat multiple sclerosis, compared to blockbuster Avonex (Interferon Beta 1a) on patients with the simplest form of the disease.

Roche Holding AG and Biogen Idec. Inc. will discontinue experimental drug development Ocrelizumab drug to treat reumathoid arthritis, due to clinical objectives not met. However the drug will still be develop to treat multiple sclerosis.

Swiss Roche Holding AG announced that weekly-dose drug to treat Type II diabetes, Taspoglutide met primary endpoint objectives, in late stage trial, compared to placebo. The trial added Metformina and Pioglitazone (Actos, Takeda Pharma)